Collegium Pharma (COLL): Management Changes A Positive - Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Collegium Pharma (COLL) Secures Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients
June 1, 2017 7:13 AM EDTCollegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced that one of the largest managed care organizations with approximately 8 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies. Effective June 1, 2017, Xtampza ER is the exclusive oxycodone extended-release product for this... More
